[go: up one dir, main page]

WO2002012471A3 - Angiotensin converting enzyme homolog and uses therefor - Google Patents

Angiotensin converting enzyme homolog and uses therefor Download PDF

Info

Publication number
WO2002012471A3
WO2002012471A3 PCT/US2001/025059 US0125059W WO0212471A3 WO 2002012471 A3 WO2002012471 A3 WO 2002012471A3 US 0125059 W US0125059 W US 0125059W WO 0212471 A3 WO0212471 A3 WO 0212471A3
Authority
WO
WIPO (PCT)
Prior art keywords
converting enzyme
angiotensin converting
uses therefor
enzyme homolog
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025059
Other languages
French (fr)
Other versions
WO2002012471A2 (en
Inventor
Susan Acton
Keith E Robison
Frank Y Hsieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/635,501 external-priority patent/US6884771B1/en
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to AU2001284794A priority Critical patent/AU2001284794A1/en
Publication of WO2002012471A2 publication Critical patent/WO2002012471A2/en
Publication of WO2002012471A3 publication Critical patent/WO2002012471A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
PCT/US2001/025059 2000-08-09 2001-08-09 Angiotensin converting enzyme homolog and uses therefor Ceased WO2002012471A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284794A AU2001284794A1 (en) 2000-08-09 2001-08-09 Angiotensin converting enzyme homolog and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/635,501 US6884771B1 (en) 1997-12-11 2000-08-09 Angiotensin converting enzyme homolog and uses therefor
US09/635,501 2000-08-09

Publications (2)

Publication Number Publication Date
WO2002012471A2 WO2002012471A2 (en) 2002-02-14
WO2002012471A3 true WO2002012471A3 (en) 2003-01-03

Family

ID=24548043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025059 Ceased WO2002012471A2 (en) 2000-08-09 2001-08-09 Angiotensin converting enzyme homolog and uses therefor

Country Status (2)

Country Link
AU (1) AU2001284794A1 (en)
WO (1) WO2002012471A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900033B2 (en) 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
WO2002098906A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
DE60324925D1 (en) * 2002-06-19 2009-01-08 Univ Health Network ACE2 ACTIVATION FOR THE TREATMENT OF HEART, LUNG, AND CHILDNESS AND BLOOD HIGH PRESSURE
EP1570854A4 (en) * 2002-10-29 2008-07-30 Gen Kondoh Drug containing angiotensin convertase
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
WO2009049022A1 (en) * 2007-10-10 2009-04-16 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
JP2011513491A (en) * 2008-03-10 2011-04-28 オレ・ファーマシューティカルズ・インコーポレーテッド Treatment of proximal gastrointestinal disorders
EP2373806A1 (en) * 2008-12-02 2011-10-12 F. Hoffmann-La Roche AG Screening assays for the identification of bace2 inhibitors
US20210238229A1 (en) * 2018-06-14 2021-08-05 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
EP4138998A4 (en) * 2020-04-24 2024-05-22 The Administrators of The Tulane Educational Fund COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE EFFECTS OF INFECTIONS CAUSED BY CORONAVIRUS THAT BIND THE ACE2 RECEPTOR
US20230183668A1 (en) * 2020-05-20 2023-06-15 Emmune, Inc. Ace2 muteins and methods of using the same
IL307872A (en) * 2021-04-20 2023-12-01 Council Queensland Inst Medical Res Novel compositions and methods for treating coronavirus infections
EP4147702A1 (en) 2021-09-13 2023-03-15 Medizinische Universität Graz Novel combination of heparin and ace2 decoys for the treatment of covid-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974644A1 (en) * 1998-07-23 2000-01-26 Ajinomoto Co., Inc. Method for producing freeze resitant yeast
EP0974664A2 (en) * 1998-05-13 2000-01-26 Smithkline Beecham Plc Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme
WO2000018899A2 (en) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and its use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974664A2 (en) * 1998-05-13 2000-01-26 Smithkline Beecham Plc Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme
EP0974644A1 (en) * 1998-07-23 2000-01-26 Ajinomoto Co., Inc. Method for producing freeze resitant yeast
WO2000018899A2 (en) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and its use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN: "Two ACEs and a heart", NATURE, vol. 417, 20 June 2002 (2002-06-20), pages 799 - 802, XP002207554 *
DATABASE EMBL [online] 1 July 2000 (2000-07-01), "Homo sapiens angiotensin converting enzyme-like protein mRNA, complete cds", XP002207559, Database accession no. AF241254 *
DATABASE GENESEQ [online] 11 April 2000 (2000-04-11), "Human MPROT15 amino acid sequence #1", XP002207557, Database accession no. AAY67310 *
DATABASE GENESEQ [online] 11 April 2000 (2000-04-11), "Human MPROT15 coding sequence", XP002207558, Database accession no. AAZ59465 *
DATABASE GENESEQ [online] 25 July 2000 (2000-07-25), "A human angiotensin converting enzyme-2 (ACE-2) protein", XP002207555, Database accession no. AAY84562 *
DATABASE GENESEQ [online] 25 July 2000 (2000-07-25), "cDNA encoding a human angiotensin converting enzyme-2 (ACE-2)", XP002207556, Database accession no. AAA12764 *
DATABASE SWALL [online] 1 October 2000 (2000-10-01), "Angiotensin converting enzyme-like protein (ACE-related carboxypeptidase ACE2)", XP002207560, Database accession no. Q9NRA7 *
DONOGHUE MARY ET AL: "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.", CIRCULATION RESEARCH, vol. 87, no. 5, 1 September 2000 (2000-09-01), pages e1 - e9, XP002207553, ISSN: 0009-7330 *
TIPNIS ET AL.: "A human homolog of Angiotensin-converting enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33238 - 33243, XP002207551 *

Also Published As

Publication number Publication date
WO2002012471A2 (en) 2002-02-14
AU2001284794A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2000018899A3 (en) Angiotensin converting enzyme homolog and its use
WO2002012471A3 (en) Angiotensin converting enzyme homolog and uses therefor
WO2002000860A3 (en) Novel proteases
WO2003052075A3 (en) Enzymes
EP0976829A3 (en) Protein-deamidating enzyme, gene encoding the same, production process therefor, and use thereof
AU2003275613A1 (en) Novel fructosyl peptide oxidase and utilization thereof
WO2002006534A3 (en) Method of diagnosing pulmonary hypertension
WO2003038444A3 (en) Biomarkers of liver function
EP0869174A3 (en) Method for cloning and producing the SpeI restriction endonuclease
WO2005040107A3 (en) Methods for making simvastatin and intermediates
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2003048309A3 (en) Thermus thermophilus nucleic acid polymerases
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2005026392A3 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
MXPA03007928A (en) Improved process for producing emulsified salad dressings background of the invention.
WO2000014206A3 (en) Mutant egiii cellulases, dna encoding such egiii compositions and methods for obtaining same
WO2003042357A3 (en) Enzymes
WO2000050631A3 (en) Compositions and methods for monitoring the modification of natural binding partners
WO2003084565A3 (en) Ve-ptp as regulator of ve-cadherin mediated processes or disorders
WO2004009786A3 (en) Modulators of leukocyte activation, bic compositions and methods of use
WO2004003162A3 (en) Enzymes
WO2003047421A3 (en) Methods and reagents for diagnosis and treatment of diabetes
WO2005115456A3 (en) METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY
WO2001014533A3 (en) Phosphomevalonate kinase (pmk) gene (erg8) from candida albicans
WO2003093439A3 (en) Enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP